Akari Therapeutics, Plc
AKTX
$10.73
$1.2112.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.02% | -29.76% | 15.56% | 9.42% | -26.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.92% | -24.87% | 20.09% | -43.85% | -41.14% |
| Operating Income | -2.92% | 24.87% | -20.09% | 43.85% | 41.14% |
| Income Before Tax | -313.33% | -38.20% | -158.65% | 74.93% | 33.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -290.15% | -40.46% | -121.07% | 74.93% | 33.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -290.15% | -40.46% | -121.07% | 74.93% | 33.44% |
| EBIT | -2.92% | 24.87% | -20.09% | 43.85% | 41.14% |
| EBITDA | -- | 24.93% | -19.90% | 43.92% | 41.07% |
| EPS Basic | -79.34% | 36.90% | 17.48% | 92.50% | 83.60% |
| Normalized Basic EPS | 59.02% | 83.93% | 56.62% | 83.70% | 83.36% |
| EPS Diluted | -79.34% | 36.90% | 17.48% | 92.50% | 83.60% |
| Normalized Diluted EPS | 59.02% | 83.93% | 56.62% | 83.70% | 83.36% |
| Average Basic Shares Outstanding | 117.54% | 122.61% | 167.91% | 234.10% | 305.71% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |